To assess differences in clinical presentation, complications, and outcomes in patients with isolated Graves disease (GD) compared to those with GD as part of an autoimmune polyglandular syndrome (APS), highlighting the significance of these differences for clinical management.
Key Findings:
Isolated GD patients exhibited Graves orbitopathy more frequently than GD1-APS and GD2-APS patients (P < .001), indicating a need for closer monitoring.
Higher rate of definitive therapy and shorter time to definitive therapy were observed in isolated GD patients (P < .001), suggesting a more aggressive treatment approach.
No significant differences in gender, thyroid function tests, TRAb titers, and thyroid volume at disease onset among the three groups, indicating similar baseline characteristics.
Interpretation:
Despite similar initial clinical and biochemical presentations, isolated GD patients experience a more severe clinical course compared to those with GD as part of APS, which may necessitate different management strategies.
Limitations:
Retrospective nature may introduce selection bias, potentially affecting the reliability of the findings.
Data limited to a single center may affect generalizability, suggesting the need for multi-center studies to validate results.
Conclusion:
Isolated Graves disease presents with more severe complications and treatment needs compared to Graves disease within the context of autoimmune polyglandular syndrome, underscoring the importance of tailored treatment approaches.
by Elisa Gatta, Ilenia Pirola, Aurora Gotti, Micaela Fredi, Pietro Bellini, Francesco Dondi, Riccardo Morandi, Claudio Casella, Francesco Bertagna, Franco Franceschini, Mario Rotondi, Carlo Cappelli
